glp-1 drugs history receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits History of GLP 1 Agonists

In addition to hepatotoxicity, VPA metabolites also cause teratogenicity by downregulating IGF2R (Insulin-like growth factor 2 receptor), RGS4 (Regulator of G protein signaling 4), COL6A3 (Collagen, type VI, alpha 3), EDNRB (Endothelin B receptor), and KLF6 (Krueppel-like factor 6) genes, as demonstrated in VPA-induced neural tube defects in a chick embryo prevalence model [89]

doi:10.1016/S0378-5173(00)00423-3 Garidel P, Pevestorf A, Bahrenburg S

Neural Regeneration Research, 2022, 17 3

China Market Analysis GLP-1 drugs are helping China expand its domestic pharmaceutical industry and global biotech influence via rapid market growth, massive manufacturing investments, and lucrative cross-border licensing deals

And self-experimentation is not the same thing as clinician-guided care

Os efeitos podem variar conforme o organismo e rotina individual